Jindan Yu (J Yu)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 23

Top Topics

Epithelial Mesenchymal Transition

Histone Deacetylase

Acute Lymphoblastic Leukemia

Long Noncoding Rna

Top Venues

Research square

Science advances

Cancer research

This page only lists publications with an associated author ORCID identifier.

Publications

Galina Gritsina, Jindan Yu
CXCR7 as a novel therapeutic target for advanced prostate cancer. Oncogene (2023)
Zhuoyuan Lin, Shivani Agarwal, Song Tan, Hongshun Shi, Xiaodong Lu, Zhipeng Tao, Xuesen Dong, Xu Wu, Jonathan C Zhao, Jindan Yu
Palmitoyl acyltransferase ZDHHC7 inhibits androgen receptor and suppresses prostate cancer. Oncogene (2023)
Marina G Ferrari, Alexis P Jimenez-Uribe, Li Wang, Luke H Hoeppner, Paari Murugan, Eunsil Hahm, Jindan Yu, Timothy M Kuzel, Sergio A Gradilone, Adrian P Mansini
Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. Oncogene (2023)
Galina Gritsina, Jindan Yu
CXCR7 as a novel therapeutic target for advanced prostate cancer. Oncogene 42 (11) (2023)
Marina G Ferrari, Alexis P Jimenez-Uribe, Li Wang, Luke H Hoeppner, Paari Murugan, Eunsil Hahm, Jindan Yu, Timothy M Kuzel, Sergio A Gradilone, Adrian P Mansini
Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. Oncogene 43 (7) (2023)
Marina G Ferrari, Alexis P Jimenez-Uribe, Li Wang, Luke H Hoeppner, Paari Murugan, Eunsil Hahm, Jindan Yu, Timothy M Kuzel, Sergio A Gradilone, Adrian P Mansini
Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. Oncogene 43 (7) (2023)
Marina G Ferrari, Alexis P Jimenez-Uribe, Li Wang, Luke H Hoeppner, Paari Murugan, Eunsil Hahm, Jindan Yu, Timothy M Kuzel, Sergio A Gradilone, Adrian P Mansini
Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. Oncogene 43 (7) (2023)
Marina G Ferrari, Alexis P Jimenez-Uribe, Li Wang, Luke H Hoeppner, Paari Murugan, Eunsil Hahm, Jindan Yu, Timothy M Kuzel, Sergio A Gradilone, Adrian P Mansini
Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. Oncogene 43 (7) (2023)
Galina Gritsina, Jindan Yu
CXCR7 as a novel therapeutic target for advanced prostate cancer. Oncogene 42 (11) (2023)
Marina G Ferrari, Alexis P Jimenez-Uribe, Li Wang, Luke H Hoeppner, Paari Murugan, Eunsil Hahm, Jindan Yu, Timothy M Kuzel, Sergio A Gradilone, Adrian P Mansini
Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. Oncogene 43 (7) (2023)
Marina G Ferrari, Alexis P Jimenez-Uribe, Li Wang, Luke H Hoeppner, Paari Murugan, Eunsil Hahm, Jindan Yu, Timothy M Kuzel, Sergio A Gradilone, Adrian P Mansini
Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. Oncogene (2023)
Marina Ferrari, Li Wang, Luke H Hoeppner, Eunsil Hahm, Jindan Yu, Timothy Kuzel, Adrian P Mansini
Myeloid differentiation factor-2/LY96, a new predictive biomarker of metastasis in prostate cancer: Clinical implications as a potential therapeutic target. Research square (2023)
Galina Gritsina, Jindan Yu
CXCR7 as a novel therapeutic target for advanced prostate cancer. Oncogene 42 (11) (2023)
Galina Gritsina, Jindan Yu
CXCR7 as a novel therapeutic target for advanced prostate cancer. Oncogene 42 (11) (2023)
Marina G Ferrari, Alexis P Jimenez-Uribe, Li Wang, Luke H Hoeppner, Paari Murugan, Eunsil Hahm, Jindan Yu, Timothy M Kuzel, Sergio A Gradilone, Adrian P Mansini
Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. Oncogene (2023)
Galina Gritsina, Jindan Yu
CXCR7 as a novel therapeutic target for advanced prostate cancer. Oncogene (2023)
Marina G Ferrari, Alexis P Jimenez-Uribe, Li Wang, Luke H Hoeppner, Paari Murugan, Eunsil Hahm, Jindan Yu, Timothy M Kuzel, Sergio A Gradilone, Adrian P Mansini
Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. Oncogene 43 (7) (2023)
Yara Rodríguez, Kenji Unno, Mihai Ioan Truica, Zachary R Chalmers, Young A Yoo, Rajita Vatapalli, Vinay Sagar, Jindan Yu, Barbara Lysy, Maha Hussain, Huiying Han, Sarki A Abdulkadir
A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer. Cancer research 82 (11) (2022)
Xiaohai Wang, Lourdes T Brea, Xiaodong Lu, Galina Gritsina, Su H Park, Wanqing Xie, Jonathan C Zhao, Jindan Yu
FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A. Oncogene 41 (37) (2022)
Xiaodong Lu, Ka-Wing Fong, Galina Gritsina, Fang Wang, Sylvan C Baca, Lourdes T Brea, Jacob E Berchuck, Sándor Spisák, Jenny Ross, Colm Morrissey, Eva Corey, Navdeep S Chandel, William J Catalona, Ximing Yang, Matthew L Freedman, Jonathan C Zhao, Jindan Yu
HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer. Nature genetics 54 (5) (2022)
Su H Park, Ka-Wing Fong, Jung Kim, Fang Wang, Xiaodong Lu, Yongik Lee, Lourdes T Brea, Kristine Wadosky, Chunming Guo, Sarki A Abdulkadir, John D Crispino, Deyu Fang, Panagiotis Ntziachristos, Xin Liu, Anqi Li, Yong Wan, David W Goodrich, Jonathan C Zhao, Jindan Yu
Posttranslational regulation of FOXA1 by Polycomb and BUB3/USP7 deubiquitin complex in prostate cancer. Science advances 7 (15) (2021)
Su H Park, Ka-Wing Fong, Ezinne Mong, M Cynthia Martin, Gary E Schiltz, Jindan Yu
Going beyond Polycomb: EZH2 functions in prostate cancer. Oncogene 40 (39) (2021)
R Vatapalli, V Sagar, Y Rodriguez, J C Zhao, K Unno, S Pamarthy, B Lysy, Jonathan F Anker, H Han, Y A Yoo, M Truica, Z R Chalmers, F Giles, Jindan Yu, Debabrata Chakravarti, B Carneiro, Sarki A Abdulkadir
Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer. Nature communications 11 (1) (2020)